Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Daoussis, Dimitrios ^a   Liossis, Stamatis Nick C ^a   Tsamandas, Athanassios C ^a   Kalogeropoulou, Christina ^a   Paliogianni, Fotini ^a   Sirinian, Chaido ^a   Yiannopoulos, Georgios ^a   Andonopoulos, Andrew P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

B cells; Fibrosis; Interstitial lung disease; Rituximab; Scleroderma; Systemic sclerosis

Indexed keywords

COLLAGEN; RITUXIMAB;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; INFLUENZA A (H1N1); INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LUNG FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN METABOLISM; RESPIRATORY TRACT INFECTION; SKIN BIOPSY; SKIN FIBROSIS; SKINFOLD; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOPSY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSIS; GREECE; HUMANS; IMMUNOLOGIC FACTORS; LINEAR MODELS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYOFIBROBLASTS; PREDICTIVE VALUE OF TESTS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, DIFFUSE; SKIN; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84867383069     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Geyer M, Muller-Ladner U. The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 2011; 40: 92-103.
2. Steen VD, Conte C, Owens GR, Medsgerta JR. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9.
3. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
4. Tashkin DP, Elashoff R, Clements PJ et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-34.
5. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004; 41: 1123-33.
6. Asano N, Fujimoto M, Yazawa N et al. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004; 165: 641-50.
7. Wollheim FA. Is Rituximab a Potential New Therapy in Systemic Sclerosis?: New Evidence Indicates the Presence of CD20-Positive B-lymphocytes in Scleroderma Skin. J Clin Rheumatol 2004; 10: 155.
8. Hasegawa M: B-lymphocytes. Shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 2010; 37: 3-10.
9. Daoussis D, Liossis SN, Tsamandas AC et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49: 271-80.
10. Daoussis D, Liossis SN, Tsamandas AC et al. Is There a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010; 40: 127-36.
11. Smith V, Van Praet JT, Vandooren B et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010; 69: 193-7.
12. Lafyatis R, Kissin E, York M et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60: 578-83.
13. Bosello S, De Santis M, Lama G et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
14. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
15. Desai SR, Veeraraghavan S, Hansell DM et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232: 560-7.
16. Valentini G, D'angelo S, Della Rossa A et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003; 62: 904-5.
17. Khanna D, Furst DE, Clements PJ et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 832-40.
18. Khanna D, Furst DE, Hays RD et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006; 65: 1325-9.
19. Saito E, Fujimoto M, Hasegawa M et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-62.
20. Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006; 169: 954-66.
21. Yoshizaki A, Iwata Y, Komura K et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63.
22. Komura K, Yanaba K, Horikawa M et al. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008; 58: 3574-84.
23. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50: 1918-27.
24. Whitfield ML, Finlay DR, Murray JI et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100: 12319-24.
25. Lafyatis R, O'hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007; 56: 3167-8.
26. Atkins SR, Turesson C, Myers JL et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006; 54: 635-41.
27. Campbell DA, Poulter LW, Janossy G, Du Bois RM. Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax 1985; 40: 405-11.
28. Wallace WA, Howie SE, Krajewski AS, Lamb D. The immunological architecture of B-lymphocyte aggregates in cryptogenic fibrosing alveolitis. J Pathol 1996; 178: 323-9.
29. Mcgonagle D, Tan AL, Madden J et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008; 47: 552-3.
30. Mayes MD, O'donnell D, Rothfield NF, Csuka ME. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004; 50: 553-7.
31. Nash RA, Mcsweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: longterm follow-up of the US multicenter pilot study. Blood 2007; 110: 1388-96.